Cargando…

LKB1: Can We Target an Hidden Target? Focus on NSCLC

LKB1 (liver kinase B1) is a master regulator of several processes such as metabolism, proliferation, cell polarity and immunity. About one third of non-small cell lung cancers (NSCLCs) present LKB1 alterations, which almost invariably lead to protein loss, resulting in the absence of a potential dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ndembe, Gloriana, Intini, Ilenia, Perin, Elisa, Marabese, Mirko, Caiola, Elisa, Mendogni, Paolo, Rosso, Lorenzo, Broggini, Massimo, Colombo, Marika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131655/ https://www.ncbi.nlm.nih.gov/pubmed/35646638 http://dx.doi.org/10.3389/fonc.2022.889826

Ejemplares similares

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation
por: Caiola, Elisa, et al.
Publicado: (2020)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
por: Caiola, Elisa, et al.
Publicado: (2016)

Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies
por: Mendogni, Paolo, et al.
Publicado: (2022)

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
por: Colombo, Marika, et al.
Publicado: (2022)

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
por: Caiola, Elisa, et al.
Publicado: (2018)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
por: Alvisi, Maria Francesca, et al.
Publicado: (2020)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

It’s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?
por: Caiola, Elisa, et al.
Publicado: (2020)

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
por: Sabatino, Maria Antonietta, et al.
Publicado: (2010)

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
por: Caiola, Elisa, et al.
Publicado: (2015)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX()
por: Iezzi, Alice, et al.
Publicado: (2016)

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
por: Ganzinelli, Monica, et al.
Publicado: (2015)

Targeting LKB1 in cancer – exposing and exploiting vulnerabilities
por: Momcilovic, M, et al.
Publicado: (2015)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
por: Affatato, Roberta, et al.
Publicado: (2020)

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells
por: Li, Huiyu, et al.
Publicado: (2022)

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC
por: Cheng, Fang-Ju, et al.
Publicado: (2020)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

LKB1 Inhibits HPV-Associated Cancer Progression by Targeting Cellular Metabolism
por: Zeng, Qinghua, et al.
Publicado: (2016)

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
por: Michelotti, Anna, et al.
Publicado: (2022)

Unveiling the Hidden Bat Diversity of a Neotropical Montane Forest
por: Chaverri, Gloriana, et al.
Publicado: (2016)

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1-mutant lung cancer
por: Kim, Jiyeon, et al.
Publicado: (2020)

LKB1IP promotes pathological cardiac hypertrophy by targeting PTEN/Akt signalling pathway
por: Tian, Mi, et al.
Publicado: (2021)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
por: Zhou, Wei, et al.
Publicado: (2014)

Advances in Oligonucleotide Aptamers for NSCLC Targeting
por: Rotoli, Deborah, et al.
Publicado: (2020)

The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
por: Favero, Andrea, et al.
Publicado: (2021)

LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
por: Qu, Shuang, et al.
Publicado: (2022)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
por: Meng, Jieru, et al.
Publicado: (2013)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small cell lung cancer (NSCLC) cells
por: Whang, Young Mi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0j6oqsk3v65frb3sbiavitbr24